.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
UBS
Deloitte
Moodys
Cantor Fitzgerald
Boehringer Ingelheim
QuintilesIMS
Colorcon
Harvard Business School
Cipla

Generated: November 20, 2017

DrugPatentWatch Database Preview

Sunovion Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for SUNOVION PHARMS INC, and what generic alternatives to SUNOVION PHARMS INC drugs are available?

SUNOVION PHARMS INC has seven approved drugs.

There are thirty US patents protecting SUNOVION PHARMS INC drugs.

There are four hundred and ninety-five patent family members on SUNOVION PHARMS INC drugs in forty-eight countries and forty-three supplementary protection certificates in fourteen countries.

Summary for Sunovion Pharms Inc

International Patents:495
US Patents:30
Tradenames:7
Ingredients:7
NDAs:7
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc
LATUDA
lurasidone hydrochloride
TABLET;ORAL200603-005Jul 12, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Sunovion Pharms Inc
LATUDA
lurasidone hydrochloride
TABLET;ORAL200603-005Jul 12, 2013RXYesNo► Subscribe► SubscribeY► Subscribe
Sunovion Pharms Inc
ARCAPTA NEOHALER
indacaterol maleate
POWDER;INHALATION022383-001Jul 1, 2011RXYesYes► Subscribe► Subscribe ► Subscribe
Sunovion Pharms Inc
SEEBRI
glycopyrrolate
POWDER;INHALATION207923-001Oct 29, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion Pharms Inc
LATUDA
lurasidone hydrochloride
TABLET;ORAL200603-003Dec 7, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-001Nov 8, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Sunovion Pharms Inc
LUNESTA
eszopiclone
TABLET;ORAL021476-003Dec 15, 2004ABRXYesYes► Subscribe► Subscribe► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-001Nov 8, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Sunovion Pharms Inc
LATUDA
lurasidone hydrochloride
TABLET;ORAL200603-001Oct 28, 2010RXYesYes► Subscribe► SubscribeY► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-004Nov 8, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Sunovion Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sunovion Pharms Inc
LUNESTA
eszopiclone
TABLET;ORAL021476-003Dec 15, 2004► Subscribe► Subscribe
Sunovion Pharms Inc
LUNESTA
eszopiclone
TABLET;ORAL021476-002Dec 15, 2004► Subscribe► Subscribe
Sunovion Pharms Inc
UTIBRON
glycopyrrolate ; indacaterol maleate
POWDER;INHALATION207930-001Oct 29, 2015► Subscribe► Subscribe
Sunovion Pharms Inc
SEEBRI
glycopyrrolate
POWDER;INHALATION207923-001Oct 29, 2015► Subscribe► Subscribe
Sunovion Pharms Inc
LUNESTA
eszopiclone
TABLET;ORAL021476-001Dec 15, 2004► Subscribe► Subscribe
Sunovion Pharms Inc
LUNESTA
eszopiclone
TABLET;ORAL021476-002Dec 15, 2004► Subscribe► Subscribe
Sunovion Pharms Inc
LUNESTA
eszopiclone
TABLET;ORAL021476-002Dec 15, 2004► Subscribe► Subscribe
Sunovion Pharms Inc
LUNESTA
eszopiclone
TABLET;ORAL021476-003Dec 15, 2004► Subscribe► Subscribe
Sunovion Pharms Inc
LUNESTA
eszopiclone
TABLET;ORAL021476-002Dec 15, 2004► Subscribe► Subscribe
Sunovion Pharms Inc
LUNESTA
eszopiclone
TABLET;ORAL021476-001Dec 15, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SUNOVION PHARMS INC drugs

Drugname Dosage Strength Tradename Submissiondate
lurasidone hydrochloride
Tablets20 mg, 40 mg, 60 mg, 80 mg, and 120 mg
LATUDA
10/28/2014
eszopiclone
Tablets1 mg, 2 mg and 3 mg
LUNESTA
12/15/2008

Non-Orange Book Patents for Sunovion Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,585,839Particles for use in a pharmaceutical composition► Subscribe
8,932,635Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation► Subscribe
8,871,274Pharmaceutical formulations for dry powder inhalers► Subscribe
5,780,632 Imide derivatives and their production and use► Subscribe
7,605,260Process for producing imide compound► Subscribe
8,258,139Method of treatment for mental disorders► Subscribe
9,040,559BETA2-adrenoceptor agonists► Subscribe
6,884,794 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets► Subscribe
7,541,022Pharmaceutical formulations for dry powder inhalers► Subscribe
7,368,104Treatment of respiratory diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sunovion Pharms Inc Drugs

Country Document Number Estimated Expiration
Spain2296831► Subscribe
World Intellectual Property Organization (WIPO)0178693► Subscribe
European Patent Office1337240► Subscribe
China1070853► Subscribe
World Intellectual Property Organization (WIPO)2009054743► Subscribe
Ukraine110012► Subscribe
Denmark2214636► Subscribe
Germany60131399► Subscribe
BrazilPI0409380► Subscribe
World Intellectual Property Organization (WIPO)2004093848► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sunovion Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00583Netherlands► SubscribePRODUCT NAME: GLYCOPYRRONIUM EN ALLE DOOR HET BASISOCTROOI BESCHERMDE; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928
166Luxembourg► SubscribePRODUCT NAME: GLYCOPYRRONIUM OU UN DE SES SELS
C0006France► SubscribePRODUCT NAME: INDACATEROL OU UN SEL DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/09/593/001 DU 20091130; REGISTRATION NO/DATE AT EEC: EU/1/09/593/001-010 DU 20091130
C0069France► SubscribePRODUCT NAME: LURASIDONE, EN PARTICULIER SOUS LA FORME DE L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, NOTAMMENT LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/14/913 20140327
C0040France► SubscribePRODUCT NAME: ESLICARBAZEPINE ACETATE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/514/001 DU 20090421; REGISTRATION NO/DATE AT EEC: EU/1/09/514/001 DU 20090421
651Luxembourg► Subscribe91651, EXPIRES: 20241130
13/014Ireland► SubscribePRODUCT NAME: GLYCOPYRRONIUM OR A SALT THEREOF; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928
1 5024-2014Slovakia► SubscribePRODUCT NAME: LURASIDON; REGISTRATION NO/DATE: EU/14/913/001 - EU/14/913/021 20140327
2014000092Germany► SubscribePRODUCT NAME: LURASIDON, INSBESONDERE EINE PHARMAZEUTISCH VERTRAEGLICHE SALZFORM UND IM SPEZIELLEN DAS HYDROCHLORIDSALZ DAVON; REGISTRATION NO/DATE: EU/1/14/913/001-021 20140321
2014034,C1884242Lithuania► SubscribePRODUCT NAME: LURASIDONUM; REGISTRATION NO/DATE: EU/1/14/913 20140321
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Baxter
QuintilesIMS
UBS
Novartis
Boehringer Ingelheim
Deloitte
Moodys
Cantor Fitzgerald
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot